Offer - Urjas Oil for just ₹ 1 X
Microcef CV 50 Dry Syrup is a prescription drug, available for use as Syrup. Other than this, Microcef CV 50 Dry Syrup has some other therapeutic uses, which have been discussed ahead.
Medical history of the patient along with age and gender determines the dosage of Microcef CV 50 Dry Syrup. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Refer to the dosage section for a detailed discussion.
Some other side effects of Microcef CV 50 Dry Syrup have been listed ahead. Such side effects of Microcef CV 50 Dry Syrup normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Microcef CV 50 Dry Syrup's effect is Mild during pregnancy and Moderate for lactating mothers. In addition, Microcef CV 50 Dry Syrup's effects on the liver, heart and kidney are discussed below in the Microcef CV 50 Dry Syrup related warnings section.
Individuals suffering from medical conditions like Jaundice must refrain from the use of Microcef CV 50 Dry Syrup since this can cause severe adverse effects. The section on Microcef CV 50 Dry Syrup contraindications lists all such conditions.
Additionally, Microcef CV 50 Dry Syrup may also adversely react with other medicines. See below for a complete list.
In addition to these precautions, you may also note that Microcef CV 50 Dry Syrup is safe while driving, and is is addictive in nature.
Microcef CV 50 Dry Syrup is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
2 - 12 years (Child) |
|
Is the use of Microcef CV 50 Dry Syrup safe for pregnant women?
Pregnant women can consume [medicine]. Though Microcef CV has mild side effects when taken during pregnany
Is the use of Microcef CV 50 Dry Syrup safe during breastfeeding?
Women who are breastfeeding can experience some moderate side effects of Microcef CV. Immediately discontinue Microcef CV if you observe any side effects. Contact your doctor, and restart using it only if your doctor considers it safe for you.
What is the effect of Microcef CV 50 Dry Syrup on the Kidneys?
Kidney can be affected by Microcef CV. If you experience any unwanted effects of this drug, stop taking it. You should take it again only after medical advice.
What is the effect of Microcef CV 50 Dry Syrup on the Liver?
Microcef CV can have moderate side effects on the liver. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Microcef CV 50 Dry Syrup on the Heart?
Very few cases of side effects of Microcef CV on the heart have been reported.
If you are suffering from any of the following diseases, you should not take Microcef CV 50 Dry Syrup unless your doctor advises you to do so -
Is this Microcef CV 50 Dry Syrup habit forming or addictive?
No, you will not get addicted to Microcef CV 50 Dry Syrup.
Interaction between Food and Microcef CV 50 Dry Syrup
Taking Microcef CV 50 Dry Syrup with food does not harm your health.
Interaction between Alcohol and Microcef CV 50 Dry Syrup
Information about the interaction of Microcef CV 50 Dry Syrup and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311